Spruce Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 47.92 million compared to USD 46.18 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to USD 1.96 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8248 USD | +2.46% | +3.16% | -71.85% |
03-15 | North American Morning Briefing : Inflation -2- | DJ |
03-14 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-71.85% | 33.13M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- SPRB Stock
- News Spruce Biosciences, Inc.
- Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023